List of Zydelig drug patents

Zydelig is owned by Gilead Sciences Inc.

Zydelig contains Idelalisib.

Zydelig has a total of 8 drug patents out of which 0 drug patents have expired.

Zydelig was authorised for market use on 23 July, 2014.

Zydelig is available in tablet;oral dosage forms.

Zydelig can be used as in combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll), for the treatment of patients with cll, fl, or sll; for the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma, for the treatment of patients with cll, fl, or sll, inhibition on pi3k kinase.

The generics of Zydelig are possible to be released after 02 September, 2033.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
USRE44638 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Aug, 2025

(2 years from now)

US8865730 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US10730879 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Mar, 2033

(10 years from now)

US9469643 GILEAD SCIENCES INC Polymorphic forms of (S)-2-(1-(9H-purin-6-ylamino)propyl)-5-fluoro-3-phenylquinazolin-4(3H)-one
Sep, 2033

(10 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8980901 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta
May, 2025

(2 years from now)

US9149477 GILEAD SCIENCES INC 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta
May, 2025

(2 years from now)

USRE44599 GILEAD SCIENCES INC Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta
Jul, 2025

(2 years from now)

US9492449 GILEAD SCIENCES INC Therapies for hematologic malignancies
Mar, 2030

(7 years from now)

Drugs and Companies using IDELALISIB ingredient

Market Authorisation Date: 23 July, 2014

Treatment: For the treatment of patients with cll, fl, or sll; Inhibition on pi3k kinase; For the treatment of patients with relapsed follicular b-cell non-hodgkin lymphoma or [relapsed] small lymphocytic lymphoma; In combination with rituximab, for the treatment of patients with relapsed chronic lymphocytic leukemia (cll)

Dosage: TABLET;ORAL

How can I launch a generic of ZYDELIG before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in